Frequently Asked Questions (FAQs) on Drug-Medical Device Combination Products

ENDORSEMENT LETTER

1. What is the validity of the endorsement letter for ancillary component?

Five (5) years, in line with product registration validity.

2. Will the endorsement letter still be valid at the point of registration approval if there is a gap of validity period between the endorsement letter issuance and the actual date of product registration approval?
3. Is an endorsement letter of ancillary medical device component still required for registration of drug-medical device combination product if the medical device is already registered with Medical Device Authority?
4. Will the name of the combination product be stated in the endorsement letter issued by the Medical Device Authority?
5. Can the endorsement letter of ancillary medical device be used for registration of multiple combination products?
6. Is the endorsement letter of ancillary drug component still required for registration of medical device-drug combination product, if the drug component used is a registered product with Drug Control Authority?
7. Is GMP (Good Manufacturing Practices) compliance evidence for manufacturer of active pharmaceutical ingredient (API) and active biological substance required for application of endorsement letter of ancillary drug component?
8. How to apply for endorsement letter of ancillary drug component?
9. How do I know the category of my ancillary drug component?
10. Where should I attach endorsement letter of ancillary medical device component, during registration of drug-medical device combination product?

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Thursday 15 August 2019, 09:10:04.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language